



US006228398B1

(12) **United States Patent**
Devane et al.

(10) **Patent No.:** **US 6,228,398 B1**
(45) **Date of Patent:** **May 8, 2001**

(54) **MULTIPARTICULATE MODIFIED RELEASE COMPOSITION**

5,837,284 11/1998 Mehta et al. 424/459

FOREIGN PATENT DOCUMENTS

(75) Inventors: **John G. Devane; Paul Stark; Niall M. M. Fanning**, all of Athlone (IE)

0 274 734 A1 * 7/1988 (EP) .
0 274 734 7/1988 (EP) .
WO9703672 2/1997 (WO) .
WO98/14168 4/1998 (WO) .

(73) Assignee: **Elan Corporation, PLC**, Dublin (IE)

OTHER PUBLICATIONS

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

Shah, et al., *J. Cont. Rel.* (1989) 9:169-175.
Giumchedi, et al., *Int. J. Pharm* (1991) 77:177-181.
Conte, et al. *Drug. Del. Ind. Pharm.* (1989) 15:2583-2596.

* cited by examiner

(21) Appl. No.: **09/566,636**

(22) Filed: **May 8, 2000**

Primary Examiner—Thurman K. Page

Assistant Examiner—Rachel Bennett

(74) *Attorney, Agent, or Firm*—Kilpatrick Stockton LLP

Related U.S. Application Data

(63) Continuation of application No. PCT/US99/25632, filed on Nov. 1, 1999.

(60) Provisional application No. 60/106,726, filed on Nov. 2, 1998.

(51) **Int. Cl.**⁷ **A61K 9/14**

(52) **U.S. Cl.** **424/484; 424/464; 424/465; 424/468; 424/469; 424/456; 424/451; 424/472**

(58) **Field of Search** 424/458, 497, 424/462, 472, 464, 468, 484, 465, 469, 456, 451

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,728,512 3/1988 Mehta et al. 424/458
4,794,001 12/1988 Mehta et al. 424/458
4,888,178 12/1989 Rotini et al. 424/468
4,904,476 2/1990 Mehta et al. 424/456
5,158,177 10/1992 Abramowitz et al. 424/458
5,445,829 * 8/1995 Paradissis et al. 424/480
5,639,476 * 6/1997 Oshlack et al. .
5,726,316 * 3/1998 Crooks et al. .

(57) **ABSTRACT**

The invention relates to a multiparticulate modified release composition that in operation delivers an active ingredient in a pulsed or bimodal manner. The multiparticulate modified release composition comprises an immediate release component and a modified release component; the immediate release component comprising a first population of active ingredient containing particles and the modified release component comprising a second population of active ingredient containing particles coated with a controlled release coating; wherein the combination of the immediate release and modified release components in operation deliver the active ingredient in a pulsed or a bimodal manner. The invention also relates to a solid oral dosage form containing such a multiparticulate modified release composition. The plasma profile achieved by the multiparticulate modified release composition is advantageous in reducing patient tolerance to the active ingredient and in increasing patient compliance by reducing dosage frequency.

37 Claims, 1 Drawing Sheet

